Kamada Ltd. Was Granted New Orphan Drug Designation by the FDA for the Treatment of Type 1 Diabetes
NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada LTD., a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, was granted an Orphan Drug Designation for its Alpha-1 Antitrypsin (AAT) product to treat type 1 diabetes.